Endocyte Shares Up 15.8% After Co. Late Wednesday Announced Presentation Of Phase 2 Data From Prostate Cancer Trial of 177Lu-PSMA-617 At 201818 ASCO Annual Meeting; PSA Reduction Results Were Previously Reported
Benzinga Newsdesk